SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Edward W. Brooke

PatientEdward W. Brooke
Date of birth1942-10-26
IdentifiersMRN HR-ML014-SYN; SSN (made up) 000-14-5063
Document date2026-05-12
AuthorHoward Bellamy, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Three-month follow-up on tamoxifen; germline result. [S]

History of Present Illness

Mr. Brooke returns three months after his last visit, about six and a half months into tamoxifen. He has missed no doses; his pill organizer is empty on the right days. Hot flashes are unchanged, mild, two or three times a week. Asked today about sexual side effects, which were not covered at the last visit, he says his libido has been lower since starting tamoxifen; erections are adequate, and he is not troubled enough to want treatment. He has had no leg swelling or pain, chest pain, breathlessness, or change in vision, and no new lump or swelling on the chest wall or in either armpit. He met the genetic counselor four weeks ago: the multigene panel found no pathogenic variant in BRCA2, BRCA1, PALB2, CHEK2, ATM, or the other genes tested, and he was given a letter to share with his relatives. He takes vitamin D daily and walks most days. [S]

ElementDetail
TamoxifenAbout six and a half months; no missed doses
Side effectsMild hot flashes; lower libido, not bothersome; no clot symptoms
GeneticsNo pathogenic germline variant; family letter given
Recurrence symptomsNone

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo fatigue or weight loss
EndocrinePositiveMild hot flashes
GenitourinaryPositiveLower libido; erections adequate; no urinary symptoms
CardiovascularNegativeNo chest pain or leg swelling or pain
EyesNegativeNo change in vision
PsychiatricNegativeMood good; PHQ-2 score 1

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Tamoxifen 20 mg oral tablet, one tablet by mouth once daily (adjuvant endocrine therapy, planned for at least five years)One tablet once dailyOral route2025-10-28activeS
Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once dailyOne tablet once dailyOral route2026-02-10activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-05-12Body height183cmS
2026-05-12Body weight82.2kgS
2026-05-12Body mass index (BMI) [Ratio]24.5kg/m2S
2026-05-12Systolic blood pressure128mm[Hg]S
2026-05-12Diastolic blood pressure74mm[Hg]S
2026-05-12Heart rate66/minS
2026-05-12Respiratory rate14/minS
2026-05-12Body temperature36.6CelS
2026-05-12Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-05-1225-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma36ng/mL30-100 ng/mLNormalS
2026-05-12Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S

Physical Exam

Vital signs recorded on 2026-05-12; see the Vital Signs section. [S]

SystemFinding
GeneralWell
Chest wallMastectomy scars healed on both sides; no nodule or skin change
Lymph nodesNo axillary, supraclavicular, or cervical nodes
ExtremitiesArm circumferences equal; no calf swelling or tenderness

Problems

ProblemClinical statusVerificationCodeProvenance
Invasive ductal carcinoma of the right male breast, central (retroareolar) portion, stage IIA (pT1c pN1a M0), grade 2, ER positive, PR positive, HER2 negative; treated by bilateral mastectomy and right axillary lymph node dissection; on adjuvant tamoxifen; synthetic modern detail linked to his publicly disclosed breast canceractiveconfirmed C50.121S — Synthetic tumor size, grade, receptor status, and stage; the diagnosis, the right side, the operation, and the spread to lymph nodes are from his public account (D).
Estrogen receptor-positive status of the breast canceractiveconfirmed Z17.0S — Synthetic receptor result; his tumor biology was not made public.
Long-term use of tamoxifen, with safety monitoring (venous thromboembolism, mood, hot flashes, sexual side effects, adherence) and bone health reviewactiveconfirmed Z79.810S — Synthetic adjuvant therapy in the modern episode.
Absence of both breasts after bilateral mastectomyactiveconfirmed Z90.13S — The double mastectomy is reported publicly (D); the coding is synthetic.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationCancer-related history and examination of both sides of the chest wall and both axillaeEvery 3 to 6 months for 3 yearsCompleted todayNo evidence of recurrence
ExaminationLymphedema assessmentEvery visit after axillary surgeryCompleted todayNo arm swelling
Medication safetyVenous thromboembolism symptoms on tamoxifenEvery visit on tamoxifenCompleted todayNone
Medication safetyHot flashes on tamoxifenEvery visit on tamoxifenCompleted todayMild and stable
Medication safetySexual side effects of tamoxifen (libido, erectile function)Every visit on tamoxifenCompleted todayLower libido; erections adequate; no treatment wanted
Medication safetySexual side effects missed at the last visitEvery visit on tamoxifenDeferredNot asked at the previous visit, a deviation from the protocol. Asked today: a mild fall in libido that he had not raised himself and that has not affected his adherence, so no harm resulted. The question is now on his visit checklist, because men often do not mention these effects unless asked
Medication safetyAdherence to tamoxifenEvery visit on tamoxifenCompleted todayNo missed doses by pill organizer
SurveyDistress and depression screen (PHQ-2)Every visitCompleted todayPHQ-2 score 1
Laboratory25-hydroxyvitamin DThree months after starting a supplementCompleted today36 ng/mL, up from 24
LaboratoryGermline multigene panel testingOnce, for every man with breast cancerUp to dateNo pathogenic variant; result reviewed with the genetic counselor four weeks ago
Self-managementGenetic counseling and information for relativesWith the germline resultCompleted todayFamily letter given; no relative is named in the record
ImagingBreast imaging (mammography)Yearly only for a remaining breast after lumpectomy, or the other breast with a predisposing variantNot indicatedBoth breasts were removed; there is no breast tissue to image
LaboratoryRoutine blood tests, tumor markers, and CT, bone scan, or PETNot recommended without symptoms in stage I to III diseaseNot indicatedNo symptoms suggesting recurrence

Goal progress:

Guideline basis: Hassett MJ, et al. Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol 2020;38(16):1849-1863 (2020); Bedrosian I, et al. Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline. J Clin Oncol 2024;42(5):584-604 (2024); Shapiro CL, et al. Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline (2019); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026)

Follow-up: Survivorship visit in three months. Medical oncology review as scheduled. Next scheduled visit 2026-08-11: survivorship visit: cancer-related history and examination, tamoxifen review, and written survivorship care plan. [S]